Difference between revisions of "OctPM pathway control state"
Beno Marija (talk | contribs) |
|||
| Line 3: | Line 3: | ||
|description='''OctPM''': [[Octanoylcarnitine]] & [[Pyruvate]] & [[Malate]]. | |description='''OctPM''': [[Octanoylcarnitine]] & [[Pyruvate]] & [[Malate]]. | ||
'''MitoPathway control state:''' FN | '''MitoPathway control state:''' [[FN]] | ||
'''SUIT protocol:''' [[ | '''SUIT protocol:''' [[SUIT-002]] | ||
This substrate combination supports N-linked flux which is typically higher than FAO capacity (F/FN<0 in the OXPHOS state). In SUIT-RP1, PMOct is induced after PM(E), to evaluate any additive effect of adding Oct. In SUIT-RP2, FAO OXPHOS capacity is measured first, testing for the effect of increasing malate concentration (compare [[malate anaplerotic pathway control state]], M alone), and pyruvate is added to compare FAO as the background state with FN as the reference state. | This substrate combination supports N-linked flux which is typically higher than FAO capacity (F/FN<0 in the OXPHOS state). In SUIT-RP1, PMOct is induced after PM(E), to evaluate any additive effect of adding Oct. In SUIT-RP2, FAO OXPHOS capacity is measured first, testing for the effect of increasing malate concentration (compare [[malate anaplerotic pathway control state]], M alone), and pyruvate is added to compare FAO as the background state with FN as the reference state. | ||
| Line 13: | Line 13: | ||
|mitopedia concept=SUIT state | |mitopedia concept=SUIT state | ||
}} | }} | ||
::: ''More details'' | |||
::::» [[FN]] | |||
::::» [[Additive effect of convergent electron flow]] | |||
::::» [[Respiratory_complexes#Respiratory_complexes_-_more_than_five |Respiratory complexes - more than five]] | |||
::::» [[OctPGM pathway control state]] | |||
::::» [[Convergent electron flow]] | |||
== OctPM | == OctPM<sub>''L''</sub> == | ||
::: | FN pathway in the LEAK state can be evaluated in the following SUIT protocols: | ||
== OctPM<sub>''P''</sub> == | |||
FN pathway in the OXPHOS state can be evaluated in the following SUIT protocols: | |||
:::*[[SUIT-002]] | |||
::::* DL-Protocol for isolated mitochondria and tissue homogenate (mt): [[SUIT-002 O2 mt D005]] | |||
::::* DL-Protocol for permeabilized fibers (pfi): [[SUIT-002 O2 pfi D006]] | |||
::::* DL-Protocol for permeabilized cells (pce): [[SUIT-002 O2 pce D007]] | |||
:::*[SUIT-005]] | |||
::::* DL-Protocol for permeabilized fibers (pfi):[[SUIT-005 O2 pfi D011]] | |||
== OctPM<sub>''E''</sub> == | |||
FN pathway in the ET state can be evaluated in the following SUIT protocols: | |||
---- | ---- | ||
Revision as of 14:38, 22 January 2019
- high-resolution terminology - matching measurements at high-resolution
OctPM pathway control state
Description
OctPM: Octanoylcarnitine & Pyruvate & Malate.
MitoPathway control state: FN
SUIT protocol: SUIT-002
This substrate combination supports N-linked flux which is typically higher than FAO capacity (F/FN<0 in the OXPHOS state). In SUIT-RP1, PMOct is induced after PM(E), to evaluate any additive effect of adding Oct. In SUIT-RP2, FAO OXPHOS capacity is measured first, testing for the effect of increasing malate concentration (compare malate anaplerotic pathway control state, M alone), and pyruvate is added to compare FAO as the background state with FN as the reference state.
Abbreviation: OctPM
Reference: MiPNet21.06 SUIT reference protocol
MitoPedia concepts:
SUIT state
OctPML
FN pathway in the LEAK state can be evaluated in the following SUIT protocols:
OctPMP
FN pathway in the OXPHOS state can be evaluated in the following SUIT protocols:
-
- DL-Protocol for isolated mitochondria and tissue homogenate (mt): SUIT-002 O2 mt D005
- DL-Protocol for permeabilized fibers (pfi): SUIT-002 O2 pfi D006
- DL-Protocol for permeabilized cells (pce): SUIT-002 O2 pce D007
- [SUIT-005]]
- DL-Protocol for permeabilized fibers (pfi):SUIT-005 O2 pfi D011
-
OctPME
FN pathway in the ET state can be evaluated in the following SUIT protocols:
